IN THE CLAIMS

1. (Currently Amended): A method of treating a human in need of cancer treatment, comprising administering a composition consisting essentially of ~~comprising~~ greater than 0.5 weight percent of a phytoestrogen based on the total weight of the composition, wherein the phytoestrogen is:

wogonin, its pharmaceutically acceptable esters and salts, or its selectively substituted analogs represented by formula (1)



(1)

wherein R^1 is hydrogen, C_1-C_6 alkyl, or C_1-C_6 alkoxy; R^2 is hydrogen, C_1-C_6 alkyl, or C_2-C_6 acyl; R^3 and R^4 are independently hydrogen, hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, or C_2-C_6 acyl; one of R^5 or R^6 is hydrogen, hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, or C_2-C_6 acyl, wherein the other of R^{5A} or R^{5B} is



wherein R^7-R^{11} are independently hydrogen, hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, or C_2-C_6 acyl; and wherein at least four of R^3-R^{11} are hydrogen;

~~and~~ a second anti-cancer agent, wherein the second anti-cancer agent is not a phytoestrogen; and

an immune stimulant.

2. (Original): The method of Claim 1, wherein the cancer is prostate cancer, breast cancer, endometrial cancer, colon cancer, lung cancer, bladder cancer, testicular cancer, ovarian cancer, thyroid cancer, or bone cancer.

3. (Cancelled):

4. (Cancelled):

5. (Currently Amended): The method of Claim 1~~3~~, wherein phytoestrogen is an extract of an herb in the family *Scutellaria.*

6. (Currently Amended): The method of Claim 1~~3~~, wherein treating comprises administering a dosage of about 0.001 mg/kg/day to about 300 mg/kg/day of the wogonin.

7. (Currently Amended): The method of Claim 1~~3~~, wherein the composition further comprises isoliquiritigenin, coumestrol, or a combination of one or more of the foregoing compounds.

8-18. (Cancelled):

19. (Previously Presented): The method of Claim 1, wherein the anti-cancer agent is oridonin, indirubin, taxol, cis-platin, camptothecan, vincristine, monocrotaline, Maytansine, homoharringtonine, colchicine, irisquinone A, irisquinone B, irisquinone C, acronycine, matrin, oxymatrin, curcumin, paricine, pariphyllin, or a combination comprising one or more of the foregoing anti-cancer agents.

20. (Cancelled):

21. (Currently Amended): The method of Claim 1~~20~~, wherein the immune stimulant is a ginsenoside, ferulic acid, mannan, synanthrin, eleutheroside A, eleutheroside B, eleutheroside C, eleutheroside D, eleutheroside E, a gynoside, beta-pachyman, inulin, a glycoprotein, polyfructose, interferons, γ-globulins, an extract of *Ganoderma lucidum*, an extract of *Coriolus versicolor*, an extract of *Poria cocos*, or a combination comprising one or more of the foregoing immune stimulants.

22. (Currently Amended): A method of treating a human in need of cancer treatment, comprising administering a composition consisting essentially of~~comprising~~ a phytoestrogen, a non-phytoestrogen anti-cancer agent, and an immune stimulant, wherein the phytoestrogen is present in an amount of greater than 0.5 weight percent based on the total weight of the composition.

23. (Previously Presented): The method of Claim 22, wherein the phytoestrogen is:

wogonin, its pharmaceutically acceptable esters and salts, or its selectively substituted analogs represented by formula (1)



(1)

wherein R^1 is hydrogen, C_1-C_6 alkyl, or C_1-C_6 alkoxy; R^2 is hydrogen, C_1-C_6 alkyl, or C_2-C_6 acyl; R^3 and R^4 are independently hydrogen, hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, or C_2-C_6 acyl; one of R^5 or R^6 is hydrogen, hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, or C_2-C_6 acyl, wherein the other of R^{5A} or R^{5B} is



wherein R^7-R^{11} are independently hydrogen, hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, or C_2-C_6 acyl; and wherein at least four of R^3-R^{11} are hydrogen.

24-25. (Cancelled):

26. (Original): The method of Claim 22, wherein the anti-cancer agent is oridonin, indirubin, taxol, cis-platin, camptothecan, vincristine, monocrotaline, Maytansine, homoharringtonine, colchicine, irisquinone A, irisquinone B, irisquinone C, acronycine, matrin, oxymatrin, curcumin, paricine, pariphyllin, or a combination comprising one or more of the foregoing anti-cancer agents.

27. (Original): The method of Claim 22, wherein the immune stimulant a ginsenoside, ferulic acid, mannan, synanthrin, eleutheroside A, eleutheroside B, eleutheroside C, eleutheroside D, eleutheroside E, gynoside, beta-pachyman, inulin, glycoproteins, polyfructose, interferons, γ-globulins, an extract of *Ganoderma lucidum*, an extract of *Coriolus versicolor*, an extracts of *Poria cocos*, or a combination comprising one or more of the foregoing immune stimulants.

28. (Original): The method of Claim 22, wherein the immune stimulant a ginsenoside, ferulic acid, mannan, synanthrin, eleutheroside A, eleutheroside B, eleutheroside C, eleutheroside D, eleutheroside E, gynoside, beta-pachyman, inulin, glycoproteins, polyfructose, interferons, γ-globulins, or a combination comprising one or more of the foregoing immune stimulants.

29. (Currently Amended): A composition, consisting essentially of~~comprising~~: greater than or equal to about 0.5 weight percent of a phytoestrogen based on the total weight of the composition and at least one anti-cancer agent, wherein the phytoestrogen is:

wogonin, its pharmaceutically acceptable esters and salts, or its selectively substituted analogs represented by formula (1)



(1)

wherein R^1 is hydrogen, C_1-C_6 alkyl, or C_1-C_6 alkoxy; R^2 is hydrogen, C_1-C_6 alkyl, or C_2-C_6 acyl; R^3 and R^4 are independently hydrogen, hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, or C_2-C_6 acyl; one of

R^5 or R^6 is hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, or C_2-C_6 acyl, wherein the other of R^{5A} or R^{5B} is



wherein R^7-R^{11} are independently hydrogen, hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, or C_2-C_6 acyl; and wherein at least four of R^3-R^{11} are hydrogen;

~~and~~ a second anti-cancer agent, wherein the second anti-cancer agent is not a phytoestrogen, and

an immune stimulant.

30-31. (Cancelled):

32. (Original): The composition of Claim 29, wherein the anti-cancer agent is oridonin, indirubin, taxol, cis-platin, camptothecan, vincristine, monocrotaline, Maytansine, homoharringtonine, colchicine, irisquinone A, irisquinone B, irisquinone C, acronycine, matrin, oxymatrin, curcumin, paricine, pariphyllin, or a combination comprising one or more of the foregoing anti-cancer agents.

33. (Original): The composition of Claim 29, wherein the anti-cancer agent is an extract of Rabdosia rubescens; and an extract of a plant selected from the group consisting of Panax pseudo-ginseng Wall, Ganoderma lucidum Karst, Scutellaria baicalensis Georgi, Glycine max, Curcuma longa, and combinations comprising one or more of the foregoing plant extracts.

34. (Cancelled):

35. (Currently Amended): The composition of Claim 2934, wherein the immune stimulant is a ginsenoside, ferulic acid, mannan, synanthrin, eleutheroside A, eleutheroside B, eleutheroside C, eleutheroside D, eleutheroside E, gynoside, beta-pachyman, inulin, glycoproteins, polyfructose, interferons, γ-globulins, an extracts of *Ganoderma lucidum*, an extract of *Coriolus versicolor*, an extracts of *Poria cocos*, or a combination comprising one or more of the foregoing immune stimulants.

36. (Currently Amended): A composition, consisting essentially ofcomprising:

greater than or equal to about 0.5 weight percent of a phytoestrogen based on the total weight of the composition;

a non-phytoestrogen anti-cancer agent; and

an immune stimulant.

37. (Cancelled):

38. (Previously Presented): The composition of Claim 36, wherein the anti-cancer agent is oridonin, indirubin, taxol, cis-platin, camptothecan, vincristine, monocrotaline, Maytansine, homoharringtonine, colchicine, irisquinone A, irisquinone B, irisquinone C, acronycine, matrin, oxymatrin, curcumin, paricine, pariphyllin, or a combination comprising one or more of the foregoing anti-cancer agents.

39. (Previously Presented): The composition of Claim 36, wherein the immune stimulant is a ginsenoside, ferulic acid, mannan, synanthrin, eleutheroside A, eleutheroside B, eleutheroside C, eleutheroside D, eleutheroside E, gynoside, beta-pachyman, inulin, glycoproteins, interferones, γ-globulins, an extract of *Ganoderma lucidum*, an extract of *Coriolus versicolor*, extracts of *Poria cocos*, or a combination comprising one or more of the foregoing immune stimulants.

40-43. (Cancelled):

44. (Previously Presented) The method of claim 2, wherein the cancer is taxol-resistant ovarian cancer.

45. (Previously Presented) The method of claim 22, wherein the cancer is taxol-resistant ovarian cancer.

46. (Previously Presented) The method of claim 1, wherein the non-phytoestrogen anti-cancer agent is oridonin.

47. (Previously Presented) The method of claim 22, wherein the non-phytoestrogen anti-cancer agent is oridonin.

48. (Previously Presented) The composition of claim 29, wherein the non-phytoestrogen anti-cancer agent is oridonin.

49. (Previously Presented) The composition of claim 36, wherein the non-phytoestrogen anti-cancer agent is oridonin.

50. (Previously Presented) The method of claim 22, wherein the immune stimulant is an extract of *Ganoderma lucidum*.

51. (Previously Presented) The composition of claim 36, wherein the immune stimulant is an extract of *Ganoderma lucidum*.

52. (New) The method of claim 1, wherein composition consists essentially of:

1 to about 40 weight percent of wogonin;

about 0.05 to about 5 weight percent of an anti-cancer agent selected from oridonin, camptothecan, vincristine, Indirubin, colchicine, ginsenosides, or a combination thereof; and

about 10 to about 98 weight percent of an immune stimulant selected from beta-pachyman, mannan, synanthrin, gynosides, and combinations comprising one or more of the

foregoing compounds; wherein all weight percents are based on the total weight of the composition.

53. (New) The method of claim 22, wherein composition consists essentially of:

1 to about 40 weight percent of wogonin;

about 0.05 to about 5 weight percent of an anti-cancer agent selected from oridonin, camptothecan, vincristine, Indirubin, colchicine, ginsenosides, or a combination thereof; and

about 10 to about 98 weight percent of an immune stimulant selected from beta-pachyman, mannan, synanthrin, gynosides, and combinations comprising one or more of the foregoing compounds; wherein all weight percents are based on the total weight of the composition.

54. (New) The composition of claim 29, wherein composition consists essentially of:

1 to about 40 weight percent of wogonin;

about 0.05 to about 5 weight percent of an anti-cancer agent selected from oridonin, camptothecan, vincristine, Indirubin, colchicine, ginsenosides, or a combination thereof; and

about 10 to about 98 weight percent of an immune stimulant selected from beta-pachyman, mannan, synanthrin, gynosides, and combinations comprising one or more of the foregoing compounds; wherein all weight percents are based on the total weight of the composition.

55. (New) The composition of claim 36, wherein composition consists essentially of:

1 to about 40 weight percent of wogonin;

about 0.05 to about 5 weight percent of an anti-cancer agent selected from oridonin, camptothecan, vincristine, Indirubin, colchicine, ginsenosides, or a combination thereof; and

about 10 to about 98 weight percent of an immune stimulant selected from beta-pachyman, mannan, synanthrin, gynosides, and combinations comprising one or more of the foregoing compounds; wherein all weight percents are based on the total weight of the composition.

56. (New) The method of claim 1, wherein composition consists essentially of:

1 to about 30 weight percent of wogonin;

about 0.1 to about 5 weight percent of oridonin; and

about 20 to about 90 weight percent of beta-pachyman; wherein all weight percents are based on the total weight of the composition.

57. (New) The method of claim 22, wherein composition consists essentially of:

1 to about 30 weight percent of wogonin;

about 0.1 to about 5 weight percent of oridonin; and

about 20 to about 90 weight percent of beta-pachyman; wherein all weight percents are based on the total weight of the composition.

58. (New) The composition of claim 29, wherein composition consists essentially of:

1 to about 30 weight percent of wogonin;

about 0.1 to about 5 weight percent of oridonin; and

about 20 to about 90 weight percent of beta-pachyman; wherein all weight percents are based on the total weight of the composition.

59. (New) The composition of claim 36, wherein composition consists essentially of:

1 to about 30 weight percent of wogonin;

about 0.1 to about 5 weight percent of oridonin; and

about 20 to about 90 weight percent of beta-pachyman; wherein all weight percents are based on the total weight of the composition.